1.1Ether oxygen as linker
The ether oxygen forms a single bond to each scaffold fragment and preserves a one-atom bridge. Its lone pairs provide a hydrogen-bond acceptor at the bridge.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
The ether oxygen forms a single bond to each scaffold fragment and preserves a one-atom bridge. Its lone pairs provide a hydrogen-bond acceptor at the bridge.
The furan ring connects the neighboring fragments through carbon atoms at positions 2 and 5. One oxygen lone pair contributes to the aromatic sextet, preserving a planar conjugated ring between the attachment points.
The nitrile carbon bonds directly to the ring carbon, and the terminal nitrogen provides a hydrogen-bond acceptor. The linear group withdraws electron density from the ring and changes its dipole.
The oxetane attaches to Z through the ring carbon opposite oxygen and provides a compact, saturated four-membered ring. The ring oxygen adds a hydrogen-bond acceptor within that ring.
The phenyl ring carries R12 and connects to the neighboring scaffold fragment at the corresponding ring carbons. The six-membered aromatic ring preserves the relative directions of those two bonds, and the two CH sites change the ring dipole.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
An instructional kit pairs a methylene-linked heterocyclic PanK activator with purified human pantothenate kinase, pantothenate, and ATP. A microplate holds matched reactions containing vehicle, the activator, or the activator with enzyme omitted. A luminescent ADP assay measures ATP turnover and lets students compare enzyme activity across the three conditions.
A carbonyl group replaces the methylene at A and connects the same two scaffold atoms through its carbon atom. The analog retains the ring atom assignments and peripheral substituents of its methylene-linked reference compound. A purified human PanK assay compares the two compounds at matched concentrations by measuring the rate of phosphopantothenate formation.
A 384-well plate holds 10 µL reactions containing purified human PanK, pantothenate, ATP, and the modulator. Ten concentrations span 1 nM to 19.7 µM in threefold steps, with three replicate wells per concentration and 0.2% dimethyl sulfoxide in every reaction. The plate incubates at 25 °C for 15 minutes before a luminescent ADP readout records turnover relative to vehicle and enzyme-free controls.
An autosampler couples quenched human PanK reactions to a hydrophilic interaction liquid chromatography system and a tandem mass spectrometer. Each reaction contains ATP, pantothenate, and either a methylene-linked modulator or its vehicle. An isotopically labeled phosphopantothenate internal standard is added at quench, and the ratio of product to internal standard is converted to concentration using a calibration curve. Timed samples establish the product formation rate for each condition.
Cultured human cells receive isotopically labeled pantothenate and a methylene-linked PanK modulator or vehicle. Replicate wells are harvested at successive time points, and polar metabolites are extracted for liquid chromatography coupled to mass spectrometry. The instrument measures labeled and unlabeled phosphopantothenate and coenzyme A, and the time courses show how treatment changes incorporation of pantothenate into pathway products.
A liquid handler dispenses one modulator concentration series into separate wells containing purified human PanK1, PanK2, or PanK3. A plate reader records ADP assay signals, and software subtracts enzyme-free background and normalizes each isoform to its vehicle control. The software fits concentration-response curves and reports maximal activity change and half-maximal response concentration for curves with a resolved plateau.
R10 is methyl in the —NR10C(O)R11 branch, placing one carbon directly on the nitrogen. The resulting tertiary amide retains the carbonyl oxygen as a hydrogen-bond acceptor.
R11 is hydroxymethyl in the —NR10C(O)R11 branch, giving a —C(O)CH2OH segment. The terminal hydroxyl acts as a hydrogen-bond donor and acceptor.
Cy2 is 3,3-difluorocyclobutyl in the amide branch and attaches to the carbonyl carbon through ring position 1. Both fluorines occupy ring position 3, opposite the attachment point.
R20 is methyl, giving an Ar1—SO2—CH3 substituent. Both sulfonyl oxygens act as hydrogen-bond acceptors, and the methyl carbon bonds directly to sulfur.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
A compound of structural Formula II or a salt thereof, wherein: B is selected from the group consisting of X2, X4, and X5 are independently selected from the group consisting of CR21, N, O, and S, and wherein X2, X4, and X5, taken together, form a 5-membered heteroaryl;B · US 9,115,120 B2 · claim 1
R1a and R1b, which are identical or different, are selected from the group consisting of: a) hydrogen; b) halogen; c) hydroxy; d) cyano; e) optionally substituted alkyl; f) alkoxy; g) haloalkoxy; and h) haloalkyl;A · US 9,056,832 B2 · claim 1
R21 is selected from the group consisting of null, hydrogen, deuterium, halogen, alkyl, haloalkyl, perhaloalkyl, heteroalkyl, hydroxyalkyl, cyano, hydroxy, alkoxy, haloalkoxy, perhaloalkoxy, alkylthio, amino, alkylamino, and dialkylamino;B · US 9,115,120 B2 · claim 1
R1 is selected from the group consisting of —Y2-alkyl-N(R4)R5, hydrogen, deuterium, halogen, alkyl, alkenyl, haloalkyl, perhaloalkyl, heteroalkyl, hydroxyalkyl, aminoalkyl, acyl, carboxylalkyl, carbonyl, carboxyl, cyano, hydroxy, alkoxy, haloalkoxy, perhaloalkoxy, oxo, alkylthio, thiolalkyl, sulfonyl, sulfonamido, alkylsulfonyl, amino, amido, alkylamino, dialkylamino, nitro, cycloalkyl, aryl, heterocycloalkyl, heteroaryl, cycloalkyloxy, aryloxy, heterocycloalkyloxy, heteroaryB · US 9,115,120 B2 · claim 1
X is selected from the group consisting of: a) —O—; b) —S—; c) —SO—; d) —SO2— e) —NR4; f) —SO2NH—; and g) —NHSO2—; wherein: R4 is selected from the group consisting of hydrogen and optionally substituted alkyl;A · US 9,056,832 B2 · claim 1
The term “lower amino,” as used herein, alone or in combination, refers to —NRR′, wherein R and R′ are independently selected from the group consisting of hydrogen, lower alkyl, and lower heteroalkyl, any of which may be optionally substituted.B · US 9,115,120 B2 · ¶ 241
R24a is selected from the group consisting of unsubstituted alkyl, unsubstituted cycloalkyl, unsubstituted aryl, and unsubstituted heteroaryl; R24b is selected from the group consisting of unsubstituted alkyl, unsubstituted cycloalkyl, unsubstituted aryl, and unsubstituted heteroaryl; t and u are each independently 0, 1, 2, or 3; and v is 1, 2, or 3; wherein: 1) when G is G-1, then E is hydroxyalkyl, E-1, or E-5; or 2) when E is hydrogen, then G is G-2, G-3, or G-4.A · US 9,056,832 B2 · claim 1
R4 and R5 are independently selected from the group consisting of hydrogen, deuterium, alkyl, alkenyl, alkynyl, haloalkyl, perhaloalkyl, heteroalkyl, hydroxyalkyl, acyl, carbonyl, carboxyl, alkoxy, haloalkoxy, perhaloalkoxy, alkylsulfonyl, sulfonamido, amido, cycloalkyl, aryl, heterocycloalkyl, heteroaryl, cycloalkylalkyl, arylalkyl, heterocycloalkylalkyl, and heteroarylalkyl, or R4 and R5, taken together, form a heterocyloalkyl or heteroaryl, any of which can be optionally sB · US 9,115,120 B2 · ¶ 29
For the purpose of the present disclosure, the term “optionally substituted cycloalkyl” as used by itself or as part of another group means that the cycloalkyl as defined above is either unsubstituted or substituted with one, two, or three substituents independently chosen from halo, nitro, cyano, hydroxy, amino, alkylamino, dialkylamino, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, aryloxy, aralkyloxy, alkylthio, carboxamido, sulfonamido, alkylcarbonyl, arylcarbonyl, alkylsuA · US 9,056,832 B2 · ¶ 530
G is: wherein: R5a and R5b, which are identical or different, are selected from the group consisting of: a) hydrogen; b) unsubstituted alkyl; c) cycloalkyl, which is unsubstituted or substituted with one, two, or three substituents independently selected from the group consisting of halo, nitro, cyano, hydroxy, amino, alkylamino, dialkylamino, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, aryloxy, aralkyloxy, alkylthio, carboxamido, sulfonamido, alkylcarbonyl, arylcarbonyl, alA · US 9,056,832 B2 · claim 1
E is selected from the group consisting of: a) hydrogen; b) heteroaryl, which is unsubstituted or substituted with one to four substituents independently selected from the group consisting of halo, nitro, cyano, hydroxy, amino, alkylamino, dialkylamino, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, aryloxy, aralkyloxy, alkylthio, carboxamido, sulfonamido, alkylcarbonyl, arylcarbonyl, alkylsulfonyl, arylsulfonyl, ureido, guanidino, carboxy, carboxyalkyl, alkyl, cycloalkyl, alkeA · US 9,056,832 B2 · claim 1
R3 is selected from the group consisting of hydrogen, deuterium, halogen, alkyl, haloalkyl, perhaloalkyl, heteroalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, acyl, carbonyl, carboxyl, cyano, cyanoalkyl, hydroxy, alkoxy, haloalkoxy, perhaloalkoxy, alkoxyalkoxy, hydroxyalkoxy, oxo, alkylthio, mercaptyl, thiol, haloalkylthio, perhaloalkylthio, cyanoalkylthio, haloalkylsulfonyl, alkylsulfonyl, alkoxyalkylsulfonyl, cyanoalkylsulfonyl, sulfonate, sulfonamido, amino, amido, alkylamiB · US 9,115,120 B2 · ¶ 27
An empty cell means only that no passage was reproduced there.
The invention relates to novel substituted pyridine compounds and the use of these compounds as blockers of voltage-gated sodium (Na+) channels.A · US 9,056,832 B2 · ¶ 2
Methods to inhibit HIF pathway activity through the degradation of the HIFα protein subunits in a human or animal subject are also provided for the treatment of diseases mediated by HIF pathway activity.B · US 9,115,120 B2 · ¶ 2
HIF mediated survival of cells in hypoxia is a major contributor to resistance to therapies, lack of durable response and the foundation of residual disease.B · US 9,115,120 B2 · ¶ 8
patent.fyi, US 2026/0356818 A1, claim 1, first published 2026-11-20T07:31:16-05:00, https://patent.fyi/US20260356818/, SHA-256 1df3060dce3f4dbc4075331ccc80217ad826e072a5b3620155083f576582584f